Literature DB >> 22367277

Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C.

Kuo-Chih Tseng1, Yun-Che Ho, Yu-Hsi Hsieh, Ning-Sheng Lai, Zhi-Hong Wen, Chin Li, Shu-Fen Wu.   

Abstract

BACKGROUND: Regulatory T cells (Tregs) play a pivotal role in the persistence of hepatitis C virus infection. The aim of this study was to evaluate the frequency and function of Tregs in patients with chronic hepatitis C (CHC).
METHODS: We enrolled 44 CHC patients with elevated alanine aminotransferase (ALT) levels (CH group), 13 CHC patients with persistent normal ALT levels (PNALT group), and 14 age-matched healthy subjects (HS group; controls). Tregs were identified as CD4+, CD25+, and forkhead box P3 (Foxp3)+ T lymphocytes, using three-color fluorescence-activated cell sorting (FACS). The frequency of Tregs was determined by calculating the percentage of CD4+CD25(high) T cells among CD4 T cells. CD127 and CD45RA were also analyzed for subsets of Tregs. The levels of serum transforming growth factor (TGF)-β and interleukin (IL)-10 in immunosuppressive assays were detected by enzyme-linked immunosorbent assay (ELISA). The immunosuppressive abilities of Tregs were evaluated by measuring their ability to inhibit the proliferation of effector cells.
RESULTS: Higher proportions of Tregs were found in the CH and PNALT groups compared with the HS group. The populations of CD127 low/negative and CD45RA negative cells were higher in the CH group than in the PNALT group. The expressions of IL-10 and TGF-β in the CH and PNALT groups were significantly higher than those in the HS group. In addition, the immunosuppressive ability of Tregs from the CH group was increased relative to that in the PNALT and the HS group.
CONCLUSIONS: CHC patients, irrespective of liver function, had higher frequencies of Tregs than healthy subjects; however, only CHC patients with inflammation showed enhanced immunosuppressive function of Tregs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367277     DOI: 10.1007/s00535-012-0544-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Natural killer cells and hepatitis C: is losing inhibition the key to clearance?

Authors:  Rachel Baden Herman; Margaret James Koziel
Journal:  Clin Gastroenterol Hepatol       Date:  2004-12       Impact factor: 11.382

Review 3.  New insights into the immunopathogenesis of chronic hepatitis C.

Authors:  Helmut M Diepolder
Journal:  Antiviral Res       Date:  2009-03-11       Impact factor: 5.970

Review 4.  Therapy of hepatitis C: patients with normal aminotransferase levels.

Authors:  P Marcellin; S Lévy; S Erlinger
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 7.  Adaptive immune responses in acute and chronic hepatitis C virus infection.

Authors:  David G Bowen; Christopher M Walker
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

Review 8.  Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity.

Authors:  Tatsuya Kanto; Norio Hayashi
Journal:  Intern Med       Date:  2006-03-15       Impact factor: 1.271

9.  Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.

Authors:  Hirotoshi Ebinuma; Nobuhiro Nakamoto; Yun Li; David A Price; Emma Gostick; Bruce L Levine; J Tobias; William W Kwok; Kyong-Mi Chang
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

10.  Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection.

Authors:  Susan Smyk-Pearson; Lucy Golden-Mason; Jared Klarquist; James R Burton; Ian A Tester; Chia C Wang; Nicole Culbertson; Arthur A Vandenbark; Hugo R Rosen
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

View more
  4 in total

1.  Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.

Authors:  Shu-Fen Wu; Chih-Wei Tseng; Yun-Che Ho; Yen-Chun Chen; Ping-Hung Ko; Yi-Ting He; Kuo-Chih Tseng
Journal:  Dig Dis Sci       Date:  2019-09-26       Impact factor: 3.199

Review 2.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

3.  Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.

Authors:  Shan-shan Su; Huan He; Ling-bo Kong; Yu-guo Zhang; Su-xian Zhao; Rong-qi Wang; Huan-wei Zheng; Dian-xing Sun; Yue-min Nan; Jun Yu
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

4.  Treg cells in the course of chronic hepatitis C virus infection partially normalize in longitudinal observation after successful DAA treatment regardless of hepatic fibrosis stage.

Authors:  Agata Zientarska; Mariusz Kaczmarek; Iwona Mozer-Lisewska; Arleta Kowala-Piaskowska; Aleksandra Witkowska; Jan Żeromski
Journal:  Clin Exp Hepatol       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.